RegulatoryCompany release

GRAIL reports Q3 revenue growth as FDA decision on Galleri test nears

🇺🇸 GRAIL, Inc. (GRAL) · Wed 04 Nov 2026

GRAIL says Galleri revenue rose 14% to $37.3 million in Q3 2026, and expects an FDA decision on its multi-cancer blood test by early Q1 2027.

GRAIL published its third-quarter 2026 results on 4 November, reporting Galleri revenue of $37.3 million, up 14% on the prior-year period. Test volume grew by about 24% to more than 56,000, while the company's net loss for the quarter was $103.6 million.

The company also pointed to a regulatory milestone. According to GRAIL, the FDA's Molecular and Clinical Genetics Panel of the Medical Device Advisory Committee voted in September in favour of approving the Galleri multi-cancer early detection blood test. GRAIL said it expects the agency's decision by early Q1 2027.

As general context, FDA advisory panels give non-binding recommendations, and the agency is not obliged to follow them when it decides on a marketing application.

GRAIL further cited publications from the NHS-Galleri and PATHFINDER 2 studies. The company said they showed more cancers detected and fewer Stage IV diagnoses. The summary available does not give detailed study figures or the panel's vote count, so those are not reported here.

What it means for your team

  • Regulatory teams tracking diagnostics should note the expected FDA decision window of early Q1 2027, following the September panel vote in favour.
  • The panel vote is a recommendation, not an approval; the final regulatory outcome and any labelling conditions remain to be seen.
  • Market-access teams may want to watch how the NHS-Galleri and PATHFINDER 2 publications feed into evidence discussions on multi-cancer early detection testing.

Company's press release (SEC filing): GRAIL, Inc. ↗

Article written by VigiEye from the official source (GRAIL, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →